Upcoming event

Tags

Show all

Intraoperative frozen section for margin evaluation during radical prostatectomy: A systematic review

European Urology Focus, November 2019

The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines

November 2019

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

The Lancet Oncology, October 2019

Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up

European Urology, October 2019

Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicentre prospective analysis

November 2019

Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres

Scandinavian Journal of Urology, October 2019

Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study

European Urology, October 2019

Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1/RT comparison”

September 2019

Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]

September 2019

Docetaxel for hormone-naïve prostate cancer: results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial NCT00268476 and sub group analysis by metastatic burden

September 2019

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

The New England Journal of Medicine, September 2019

Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers

European Urology, September 2019

Next